EUVIMEDObjevte EUVIMED
Übersichtsarbeit

SGLT2 inhibitors and autophagy in diabetes

Habib Yaribeygi iD, Mina Maleki iD, Stephen L Atkin, Tannaz Jamialahmadi iD, Amirhossein Sahebkar iD

Cell Biochemistry and Function · 2023-06 · 41 (4) · 392-398

DOI: 10.1002/cbf.3792 ↗

At a glance

Übersichtsarbeit in Cell Biochemistry and Function, published online on 2023-04-10. Written by Habib Yaribeygi and 4 co-authors. Institution: Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hyperglycemia. Cited 11 times so far (Crossref); 80 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Autophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications. Therefore, autophagy‐modifying therapy may be of value to prevent the development of complications. Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs that achieve normoglycemia through causing overt glycosuria. There is evidence that these drugs may have pleiotropic extra‐glycemic benefits, but their effect on the autophagy process is unclear; therefore, this review was undertaken to clarify the possible effects of SGLT2is on autophagy.

Subjects

MeSH terms (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HyperglycemiaAnimalsHumansHypoglycemic AgentsAutophagyMammals

Author keywords

SGLT2iautophagydiabetes mellitussodium-glucose cotransporter 2 inhibitorssodium-hydrogen exchangers

Substances

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Authors and institutions

  • Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran.
  • Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Busaiteen, Bahrain.
  • Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID profiles: Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, Amirhossein Sahebkar

Cite

APA

Yaribeygi, H., Maleki, M., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2023). SGLT2 inhibitors and autophagy in diabetes. Cell Biochemistry and Function, 41(4), 392-398. https://doi.org/10.1002/cbf.3792

Vancouver

Yaribeygi H, Maleki M, Atkin SL, Jamialahmadi T, Sahebkar A. SGLT2 inhibitors and autophagy in diabetes. Cell Biochemistry and Function. 2023;41(4):392-398. doi:10.1002/cbf.3792

BibTeX
@article{Yaribeygi2023,
  author = {Yaribeygi, Habib and Maleki, Mina and Atkin, Stephen L and Jamialahmadi, Tannaz and Sahebkar, Amirhossein},
  title = {SGLT2 inhibitors and autophagy in diabetes},
  journal = {Cell Biochemistry and Function},
  year = {2023},
  volume = {41},
  number = {4},
  pages = {392--398},
  doi = {10.1002/cbf.3792}
}
Start for free →